1. Home
  2. VCIG vs BCDA Comparison

VCIG vs BCDA Comparison

Compare VCIG & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VCI Global Limited

VCIG

VCI Global Limited

SELL

Current Price

$9.20

Market Cap

12.5M

ML Signal

SELL

BCDA

BioCardia Inc.

HOLD

Current Price

$1.29

Market Cap

12.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VCIG
BCDA
Founded
2013
N/A
Country
Malaysia
United States
Employees
N/A
17
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.5M
12.4M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
VCIG
BCDA
Price
$9.20
$1.29
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
1.0M
56.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.81
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$1.00
52 Week High
$15.45
$3.20

Technical Indicators

Market Signals
Indicator
VCIG
BCDA
Relative Strength Index (RSI) 96.34 57.42
Support Level $0.75 $1.24
Resistance Level $15.45 $1.33
Average True Range (ATR) 0.25 0.08
MACD 0.57 0.02
Stochastic Oscillator 82.08 80.43

Price Performance

Historical Comparison
VCIG
BCDA

About VCIG VCI Global Limited

VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: